Apixaban: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Apixaban appears in the FDA drug-label database. Marketed as apixaban.
- Drug class
- Factor Xa Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Factor Xa Inhibitors (as stated on the FDA label)
- Boxed warning
- The FDA label for Apixaban carries a boxed warning (the FDA's most serious warning). See the full label for details.
FDA-approved use
& USAGE Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation Apixaban tablets are indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery Apixaban tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis Apixaban tablets are indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism Apixaban tablets are indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE A…
Phase breakdown
Conditions being studied
Recruiting trials involving Apixaban
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
- Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
- Apixaban in Thrombocytopenia
- Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis
- Bariatric Surgery and Pharmacokinetics of Apixaban
- COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
- Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
- Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
- Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
- Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
- Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Common questions
Is Apixaban FDA-approved?
Yes, marketed as apixaban. Its FDA label carries a boxed warning.
How many recruiting trials involve Apixaban?
13 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.